Next For Genentech: Tackling Neuroscience And Infectious Disease
Executive Summary
Having built a heritage on the discovery of breakthrough medications in oncology, immunology and tissue growth and repair, Genentech is now turning its sights to tackling diseases in two new therapeutic areas: neuroscience and infectious disease
You may also be interested in...
Genentech Partners In Pain With Xenon
As part of its burgeoning efforts in neuroscience, Genentech will discover and develop compounds and companion diagnostics for the treatment of pain, not an area the company historically has played in.
Roche's CNS Drug Pipeline Matures: More Investment, More Promise
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.
Roche's CNS Drug Pipeline Matures: More Investment, More Promise
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.